USA - engelsk - NLM (National Library of Medicine)

h e b - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - to help reduce bacteria on the skin

USA - engelsk - NLM (National Library of Medicine)

h e b - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - to help reduce bacteria on the skin

USA - engelsk - NLM (National Library of Medicine)

h e b - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - to help reduce bacteria on the skin

USA - engelsk - NLM (National Library of Medicine)

h e b - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - to help reduce bacteria on the skin

USA - engelsk - NLM (National Library of Medicine)

h e b - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - to help reduce bacteria on the skin

USA - engelsk - NLM (National Library of Medicine)

orchidpharma inc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome pantoprazole is contraindicated in patients with known

USA - engelsk - NLM (National Library of Medicine)

orchidpharma inc - modafinil (unii: r3uk8x3u3d) (modafinil - unii:r3uk8x3u3d) - modafinil 100 mg - modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (osa), or shift work disorder (swd). limitations of use in osa, modafinil tablets are indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. if continuous positive airway pressure (cpap) is the treatment of choice for a patient, a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating and during treatment with modafinil tablets for excessive sleepiness. modafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil or its inactive ingredients [see warnings and precautions (5.1, 5.2, 5.3)] . teratogenic effects pregnancy category c there are no adequate and well-controlled studies of modafinil in pregnant women. intrauterine growth restriction and spontaneous abortion have been reported in association with modafinil (a mixture of r- and s-modaf

USA - engelsk - NLM (National Library of Medicine)

orchidpharma inc - terbinafine hydrochloride (unii: 012c11zu6g) (terbinafine - unii:g7riw8s0xp) - terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (koh) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. terbinafine tablets are contraindicated in patients with: - chronic or active liver disease [see warnings and precautions (5.1)] - history of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see adverse reactions (6.2)] ​ risk summary available data from postmarketing cases on the use of terbinafine tablets in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, terbinafine did not cause malformations or any harm to the fetus when administered to pregnant rabbits and rats during the period of organogenesis at oral doses

India - engelsk - Central Drugs Standard Control Organization

orchid hc. - alfacalcidol - cap - 0.25mcg - 10

India - engelsk - Central Drugs Standard Control Organization

orchid hc. - amlodipine - tab - 5mg - 10